Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cytel, FDA ink research agreement

This article was originally published in The Gray Sheet

Executive Summary

Software and clinical trial design services company Cytel signs a cooperative research and development agreement with FDA's device center to develop a software package to help sponsors and regulators utilize Bayesian statistical methods in clinical trials, the firm announces June 22. FDA encourages Bayesian methods as a way to factor in prior clinical evidence to make new device trials smaller, faster and cheaper, but many physicians are not familiar with the techniques (1"The Gray Sheet" June 22, 2009)
Advertisement

Related Content

MedCAC Favors Applying Bayesian Statistics To CMS Policy Decisions
MedCAC Favors Applying Bayesian Statistics To CMS Policy Decisions

Topics

Advertisement
UsernamePublicRestriction

Register

MT027592

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel